ERBB2 and breast carcinoma: Both HER2-positive CTCs and HER2-negative CTCs have been detected in patients with HER2-negative primary tumors (e.g., TNBCs) after adjuvant chemotherapy for the management of their primary breast cancer [9,10,11,12].